Pharmapack Europe & CPHI have outlined key trends for pharma in 2025, highlighting the return of funding liquidity—via increased VC investments and PE capital for M&A.
Evaluate, a provider of market insights for the pharmaceutical industry, has released its 2025 Preview report featuring updated forecasts for the biopharma market for 2025.
Cartherics Pty has announced that it has been awarded a $300K G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials.
Investors worldwide are scouring for their next big win after the door to the extremely lucrative obesity market was opened by pharmaceutical giants Novo Nordisk and Eli Lilly. Now benefiting on the Swedish stock exchange is a smaller biotech company
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the close of a Series B extension financing round with an investment from EQT Life Sciences.
ARC Innovation announced the successful $5.1 million funding round of Starget Pharma, a startup specialising in precise cancer diagnosis and targeted radiotherapy.
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, has announced it has secured £1 million in grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy).
Cytomos has raised £5 million to scale up production of its first commercial product, Celledonia, built on its cell-analysis technology platform AuraCyt.
ARC Innovation announced the successful $5.1 million funding round of Starget Pharma, a startup specialising in precise cancer diagnosis and targeted radiotherapy.
This week’s budget saw several major announcements for the UK life sciences sector. Yogan Patel, head of life sciences for MHA, the UK member firm of the global Baker Tilly network, explores what’s been announced and what it means for the industry.
